More than 30% of all tumor diseases of the reproductive system fall on ovarian cancer. Ovarian cancer ranks fourth place in the world among malignant diseases, Europe mortality for 2013 amounted to 3.6-9.3 per 100,000 women.
Content
Survival among women with discovered ovarian tumor directly
depends on early and reliable diagnostics, because in the early stages
Symptoms are unclear and non-permanent and similar to symptoms
adnexita.
The standard method for identifying malignant formations in the ovaries is the blood test to the monacker CA125, CT and MRI. The definition of CA125 in the diagnosis undoubtedly plays an important role, but it should be noted that the sensitivity of the monacker at the I and II stages of ovarian cancer are quite low, and no more than 50% of women are observed.
It is also worth noting that the elevated level of CA125 does not indicate an oncological disease of the ovaries, and maybe talking about benign diseases, endometriosis and other localization tumors.
A number of studies in the field of malignant ovarian tumors showed that oncomarker Ne4 — It is a more sensitive and specific oncomarker to identify the risks of ovarian cancer. Conducted tests have shown that the level of non-4 is elevated in half patients with oncological diseases of the ovaries, while the level of CA125 in the same patients is normal.
Based on the research, it can be concluded that the combination of tests for oncomarkers non4 and CA125 allows you to diagnose the development of crayfish cancer in the early stages, which will reduce mortality and pick up timely therapy.
